Synopsis Renal Impairment is a known co-morbidity in 20–30% of patients with refractory/relapse multiple myeloma. This impacts the pharmacokinetics of drugs that are excreted by kidneys. The present study investigates the safety, efficacy and pharmacokinetics of pomalidomide and low dose dexamethasone in patients moderate or severe renal impairment including hemodialysis. This week’s “MED FACT” discusses a clinical trial from Blood, “MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis”.
Authors: P. Sonneveld et. al., Key Takeaways The pharmacokinetic profile suggests pomalidomide administration after hemodialysis as significant amount is cleared from blood. Objective: To evaluate safety and efficacy of pomalidomide and low…
